Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition

KRAS GTPases are activated in one-third of cancers and KRAS(G12C) is the most common activating alteration in lung adenocarcinoma(1,2). KRAS(G12C) inhibitors(3,4) are in Phase-I clinical trials and early data show partial responses in ~50% of lung cancer patients. How cancer cells bypass inhibition,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nature
Autors principals: Xue, Jenny Y., Zhao, Yulei, Aronowitz, Jordan, Mai, Trang T., Vides, Alberto, Qeriqi, Besnik, Kim, Dongsung, Li, Chuanchuan, de Stanchina, Elisa, Mazutis, Linas, Risso, Davide, Lito, Piro
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7308074/
https://ncbi.nlm.nih.gov/pubmed/31915379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41586-019-1884-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars